|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Finally, p53 mutation correlates with highly expressed sterol biosynthesis genes in human breast tumors.
|
22265415 |
2012 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
We previously showed that the anti-malarial Chloroquine, a 4-alkylamino substituted quinoline, is a p53 activator and reduced the incidence of breast tumors in animal models.
|
22142888 |
2012 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Staining of PLK1 was observed in 11% of primary breast tumours and was significantly associated with the presence of TP53 mutation (P = 0.0063).
|
22405092 |
2012 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In addition, the Arg72Pro genotype of 116 breast tumors was determined, and correlated with intratumoral mRNA expression of TP53 and its key target genes MDM2, p21, BAX, and PERP, as quantified by qRT-PCR.
|
23071787 |
2012 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We also found that MCT1 expression was increased in human breast tumors harboring p53 mutations and coincident features of hypoxia, with higher MCT1 levels associated with poorer clinical outcomes.
|
22184616 |
2012 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Here we present a molecular characterization of 50 p53 null mammary tumors compared with other mouse models and human breast tumor subtypes.
|
21633010 |
2012 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
This prognostic value may rely in part on the fact that p53 plays a role in the antiproliferative and apoptotic activities of chemotherapy regimens used to treat breast tumors.
|
20549698 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Estrogen receptor negative (ER(-ve)) and p53 mutant breast tumors are highly aggressive and have fewer treatment options.
|
22027149 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Comparison of DGGE and immunohistochemistry in the detection of TP53 variants in a Brazilian sample of sporadic breast tumors.
|
21107729 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A significant proportions of breast tumors (20-30%) carry mutations in TP53 gene and these mutations are associated with poor survival and poor response to several types of chemotherapeutic treatments.
|
20221692 |
2011 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Our results show that kin17 expression was markedly increased in clinical breast tumors and was associated with tumor grade, Ki-67 expression, p53 mutation status and progesterone receptor expression, which were assessed in a clinicopathologic characteristics review.
|
21980430 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
FAK mRNA expression was also found to correlate with TP53 mutation status in a series of breast tumors.
|
21071137 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The patient group with the mutant p53 breast tumour-expressing p53γ isoform had low cancer recurrence and an overall survival as good as that of patients with wild-type p53 breast cancer.
|
21251329 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
|
21056685 |
2011 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Furthermore, loss of p53 correlates with a decrease in the level of miR-200c, but an increase in the expression of EMT and stemness markers, and development of a high tumour grade in a cohort of breast tumours.
|
21336307 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We found that the high incidence of protein truncating TP53 mutations and the pattern and amount of genomic aberrations specific for BRCA1-mutated breast tumors are also characteristic for BLBCs and different from luminal breast tumors.
|
21118481 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations.
|
20482849 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.
|
20064791 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study.
|
20805372 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Moreover, intratumoral injections of Ad-ING4 in nude mice bearing mutant p53 MDA-MB-231 breast tumors remarkably inhibited the human breast xenografted tumor growth and reduced CD34 expression of tumor vessels and microvessel density.
|
20707719 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
TP53 mutations in breast cancer: association with ductal histology and early relapse of disease.
|
18949740 |
2009 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
|
19147582 |
2009 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Previously, we found that p53 genotype was correlated with ER expression and response to tamoxifen in mammary tumors arising in mouse mammary tumor virus-Wnt-1 transgenic mice.
|
19351845 |
2009 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
However, whereas the majority of sporadic breast tumors that stained negative for p53 accumulation had wild-type TP53, the majority of BRCA1-associated breast tumors that stained negative for p53 accumulation had protein-truncating TP53 mutations (nonsense, frameshift, and splice mutations).
|
19336573 |
2009 |